141 related articles for article (PubMed ID: 34413161)
1. Identification of Food-Derived Isoflavone Sulfates as Inhibition Markers for Intestinal Breast Cancer Resistance Proteins.
Agustina R; Masuo Y; Kido Y; Shinoda K; Ishimoto T; Kato Y
Drug Metab Dispos; 2021 Nov; 49(11):972-984. PubMed ID: 34413161
[TBL] [Abstract][Full Text] [Related]
2. The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect.
Rigalli JP; Scholz PN; Tocchetti GN; Ruiz ML; Weiss J
Eur J Nutr; 2019 Feb; 58(1):139-150. PubMed ID: 29101532
[TBL] [Abstract][Full Text] [Related]
3. In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.
Merino G; Perez M; Real R; Egido E; Prieto JG; Alvarez AI
Pharm Res; 2010 Oct; 27(10):2098-105. PubMed ID: 20607366
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo.
Zhang Y; Shipkova PA; Warrack BM; Nelson DM; Wang L; Huo R; Chen J; Panfen E; Chen XQ; Fancher RM; Ruan Q; Christopher LJ; Xue Y; Sinz M; Shen H
Drug Metab Dispos; 2023 Jul; 51(7):851-861. PubMed ID: 37055191
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of the glucuronide and sulfate conjugates of genistein and daidzein in breast cancer resistance protein 1 knockout mice.
Álvarez AI; Vallejo F; Barrera B; Merino G; Prieto JG; Tomás-Barberán F; Espín JC
Drug Metab Dispos; 2011 Nov; 39(11):2008-12. PubMed ID: 21828252
[TBL] [Abstract][Full Text] [Related]
6. Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter.
Bircsak KM; Aleksunes LM
Curr Drug Metab; 2015; 16(2):124-40. PubMed ID: 26179608
[TBL] [Abstract][Full Text] [Related]
7. Modulation of monepantel secretion into milk by soy isoflavones.
Gunes Y; Okyar A; Krajcsi P; Fekete Z; Ustuner O
J Vet Pharmacol Ther; 2023 May; 46(3):185-194. PubMed ID: 36448496
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids.
Tamaki H; Satoh H; Hori S; Ohtani H; Sawada Y
Drug Metab Pharmacokinet; 2010; 25(2):170-9. PubMed ID: 20460823
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine.
Zhu W; Xu H; Wang SW; Hu M
AAPS J; 2010 Dec; 12(4):525-36. PubMed ID: 20582579
[TBL] [Abstract][Full Text] [Related]
11. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
Lou Y; Guo Z; Zhu Y; Zhang G; Wang Y; Qi X; Lu L; Liu Z; Wu J
J Ethnopharmacol; 2019 Jan; 228():82-91. PubMed ID: 30243825
[TBL] [Abstract][Full Text] [Related]
12. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport Across Caco-2 Cell Monolayers.
Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
Drug Metab Dispos; 2020 Jun; 48(6):491-498. PubMed ID: 32193356
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer resistance protein exports sulfated estrogens but not free estrogens.
Imai Y; Asada S; Tsukahara S; Ishikawa E; Tsuruo T; Sugimoto Y
Mol Pharmacol; 2003 Sep; 64(3):610-8. PubMed ID: 12920197
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
16. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Mishra J; Simonsen R; Kumar N
J Biol Chem; 2019 Nov; 294(48):18337-18348. PubMed ID: 31653704
[TBL] [Abstract][Full Text] [Related]
17. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
Perry J; Ghazaly E; Kitromilidou C; McGrowder EH; Joel S; Powles T
Mol Cancer Ther; 2010 Dec; 9(12):3322-9. PubMed ID: 20889729
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ABCG2/BCRP transporter by soy isoflavones genistein and daidzein: effect on plasma and milk levels of danofloxacin in sheep.
Perez M; Otero JA; Barrera B; Prieto JG; Merino G; Alvarez AI
Vet J; 2013 May; 196(2):203-8. PubMed ID: 23083838
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.
Yang Z; Zhu W; Gao S; Yin T; Jiang W; Hu M
Drug Metab Dispos; 2012 Oct; 40(10):1883-93. PubMed ID: 22736306
[TBL] [Abstract][Full Text] [Related]
20. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
